ATNM 外匯新聞
Actinium Says Phase 3 SIERRA Trial Results Of Iomab-B Shows Improving OS For AML Patients
Actinium Pharmaceuticals, Inc. (ATNM) announced Thursday that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17.
RTTNews
|
58天前
